Peter G. Traber - 25 Sep 2023 Form 4 Insider Report for SELECTA BIOSCIENCES INC (RNAC)

Reporting relationship: Chief Medical Officer
Issuer ticker: RNAC
Reported as of: 25 Sep 2023
Net transaction value: -$747
SEC form: 4
Accepted by SEC: 26 Sep 2023, 18:00:28 UTC
Prior SEC filing: 06 Jan 2023
Source filing: View source filing
Reporting owner signature: /s/ Matthew Bartholomae, Attorney-in-Fact for Peter G. Traber

Key filing fact

Peter G. Traber filed Form 4 for SELECTA BIOSCIENCES INC (RNAC) on 26 Sep 2023.

Key facts

This page summarizes Peter G. Traber's Form 4 filing for SELECTA BIOSCIENCES INC (RNAC).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 26 Sep 2023, 18:00.

Change

Previous filing in this sequence was filed on 06 Jan 2023.
Current net transaction value: -$747.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

SELB transaction

Common Stock

Sale

Transaction value: $747
Shares: -705
Change %: -0.16%
Price: $1.06
Shares after: 451,826
Date: 25 Sep 2023
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees.

Footnote F2

Includes 6,410 shares of common stock purchased under the Issuer's Employee Stock Purchase Program during the contribution period between September 1, 2022 and February 28, 2023.